301 related articles for article (PubMed ID: 23966300)
1. Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Lichtenberger BM; Gerber PA; Holcmann M; Buhren BA; Amberg N; Smolle V; Schrumpf H; Boelke E; Ansari P; Mackenzie C; Wollenberg A; Kislat A; Fischer JW; Röck K; Harder J; Schröder JM; Homey B; Sibilia M
Sci Transl Med; 2013 Aug; 5(199):199ra111. PubMed ID: 23966300
[TBL] [Abstract][Full Text] [Related]
2. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Mascia F; Lam G; Keith C; Garber C; Steinberg SM; Kohn E; Yuspa SH
Sci Transl Med; 2013 Aug; 5(199):199ra110. PubMed ID: 23966299
[TBL] [Abstract][Full Text] [Related]
3. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
[TBL] [Abstract][Full Text] [Related]
5. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
Zhang Z; Xiao C; Gibson AM; Bass SA; Khurana Hershey GK
J Immunol; 2014 Feb; 192(3):859-66. PubMed ID: 24337738
[TBL] [Abstract][Full Text] [Related]
6. Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling.
Chung YL; Pui NN
J Dermatol Sci; 2011 Dec; 64(3):163-73. PubMed ID: 21924869
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2 regulates epidermal chemokine expression and skin inflammation.
Pastore S; Mascia F; Mariotti F; Dattilo C; Mariani V; Girolomoni G
J Immunol; 2005 Apr; 174(8):5047-56. PubMed ID: 15814736
[TBL] [Abstract][Full Text] [Related]
8. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
Satoh TK; Mellett M; Meier-Schiesser B; Fenini G; Otsuka A; Beer HD; Rordorf T; Maul JT; Hafner J; Navarini AA; Contassot E; French LE
J Clin Invest; 2020 Mar; 130(3):1417-1430. PubMed ID: 31805013
[TBL] [Abstract][Full Text] [Related]
9. Phosphatase Regulator NIPP1 Restrains Chemokine-Driven Skin Inflammation.
Verbinnen I; Jonkhout M; Liakath-Ali K; Szekér K; Ferreira M; Boens S; Rouget R; Nikolic M; Schlenner S; Van Eynde A; Bollen M
J Invest Dermatol; 2020 Aug; 140(8):1576-1588. PubMed ID: 31972250
[TBL] [Abstract][Full Text] [Related]
10. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.
Joly-Tonetti N; Ondet T; Monshouwer M; Stamatas GN
BMC Cancer; 2021 Jan; 21(1):5. PubMed ID: 33402117
[TBL] [Abstract][Full Text] [Related]
11. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
12. Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin.
Nagao K; Kobayashi T; Moro K; Ohyama M; Adachi T; Kitashima DY; Ueha S; Horiuchi K; Tanizaki H; Kabashima K; Kubo A; Cho YH; Clausen BE; Matsushima K; Suematsu M; Furtado GC; Lira SA; Farber JM; Udey MC; Amagai M
Nat Immunol; 2012 Jun; 13(8):744-52. PubMed ID: 22729248
[TBL] [Abstract][Full Text] [Related]
13. Superoxide Dismutase 3 Inhibits LL-37/KLK-5-Mediated Skin Inflammation through Modulation of EGFR and Associated Inflammatory Cascades.
Agrahari G; Sah SK; Nguyen CT; Choi SS; Kim HY; Kim TY
J Invest Dermatol; 2020 Mar; 140(3):656-665.e8. PubMed ID: 31465746
[TBL] [Abstract][Full Text] [Related]
14. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
Liu Y; Jiang X; Gu Y; Chen Y
Int Immunopharmacol; 2019 Apr; 69():79-87. PubMed ID: 30682720
[TBL] [Abstract][Full Text] [Related]
15. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
16. GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib.
Chen LY; You Q; Lv DZ; Li SH; Zhang SY
Acta Pharmacol Sin; 2022 Jun; 43(6):1534-1543. PubMed ID: 34552215
[TBL] [Abstract][Full Text] [Related]
17. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
18. Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
Bichsel KJ; Gogia N; Malouff T; Pena Z; Forney E; Hammiller B; Watson P; Hansen LA
PLoS One; 2013; 8(7):e69368. PubMed ID: 23894460
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
Surguladze D; Deevi D; Claros N; Corcoran E; Wang S; Plym MJ; Wu Y; Doody J; Mauro DJ; Witte L; Busam KJ; Pytowski B; Rodeck U; Tonra JR
Cancer Res; 2009 Jul; 69(14):5643-7. PubMed ID: 19584274
[TBL] [Abstract][Full Text] [Related]
20. Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling.
Potter CS; Wang Z; Silva KA; Kennedy VE; Stearns TM; Burzenski L; Shultz LD; Hogenesch H; Sundberg JP
PLoS One; 2014; 9(1):e85666. PubMed ID: 24465642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
